These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 25480887

  • 1. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dörner T, Tzioufas A, Gottenberg JE, Solans Laqué R, Mandl T, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Priori R, Bartoloni E, Goeb V, Praprotnik S, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Meiners P, Brito-Zerón P, Vitali C, Mariette X, EULAR Sjögren's Task Force.
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Yves Hatron P, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Saliou P, Pers JO, Seror R, Saraux A.
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R, Gottenberg JE, Devauchelle-Pensec V, Dubost JJ, Le Guern V, Hayem G, Fauchais AL, Goeb V, Hachulla E, Hatron PY, Larroche C, Morel J, Pedriger A, Puechal X, Rist S, Saraux A, Sene D, Sibilia J, Vittecoq O, Zarnitsky C, Labetoulle M, Ravaud P, Mariette X.
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
    [Abstract] [Full Text] [Related]

  • 7. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [Abstract] [Full Text] [Related]

  • 8. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Mariette X, Vitali C.
    J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?
    Lendrem D, Mitchell S, McMeekin P, Gompels L, Hackett K, Bowman S, Price E, Pease CT, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Ng WF, UK primary Sjögren’s Syndrome Registry.
    Rheumatology (Oxford); 2015 Apr; 54(4):655-9. PubMed ID: 25240612
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
    Milic V, Colic J, Cirkovic A, Stanojlovic S, Damjanov N.
    PLoS One; 2019 Apr; 14(12):e0226498. PubMed ID: 31891590
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.
    Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C, EULAR Sjögren's Task Force.
    Ann Rheum Dis; 2010 Jun; 69(6):1103-9. PubMed ID: 19561361
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
    Kobayashi I, Okura Y, Ueki M, Tozawa Y, Takezaki S, Yamada M, Ariga T.
    Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
    [Abstract] [Full Text] [Related]

  • 17. The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients.
    Cho HJ, Yoo JJ, Yun CY, Kang EH, Lee HJ, Hyon JY, Song YW, Lee YJ.
    Rheumatology (Oxford); 2013 Dec; 52(12):2208-17. PubMed ID: 24023247
    [Abstract] [Full Text] [Related]

  • 18. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index.
    Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, Bootsma H, Theander E, Tzioufas A, Vitali C, Ravaud P, European League Against Rheumatism Sjögren's Task Force.
    Arthritis Care Res (Hoboken); 2010 Apr; 62(4):551-8. PubMed ID: 20391511
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
    Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W, TWINSS study group.
    Lancet; 2024 Aug 10; 404(10452):540-553. PubMed ID: 39096929
    [Abstract] [Full Text] [Related]

  • 20. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
    Bai W, Yang F, Xu H, Wei W, Li H, Zhang L, Zhao Y, Shi X, Zhang Y, Zeng X, Leng X.
    Trials; 2023 Feb 15; 24(1):112. PubMed ID: 36793118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.